The global antacids market size was valued at USD 7.71 billion in 2025 and is projected to grow from USD 8.05 billion in 2026 to USD 11.33 billion by 2034, registering a CAGR of 4.37% during the forecast period (2026–2034). North America dominated the antacids market with a share of 42.36% in 2025.
Antacid is a medicine that neutralizes or reduces excess stomach acid. It is commonly used to relieve symptoms such as heartburn, acid indigestion, and stomach discomfort caused by excess gastric acid. Antacids are tracked under HSN Code 3004 (medicaments for therapeutic or prophylactic uses) and SIC Code 2834 (pharmaceutical preparations).
The antacids market demand is driven by the rising prevalence of acid reflux, heartburn, and indigestion, along with the need for quick relief from digestive discomfort. Pharmaceutical companies are offering diverse formulations and improving product availability, contributing to the antacids market growth.
By Type
By Active Ingredient
By Distribution Channel
Download a Free Sample To learn more about this report,
Digital Monitoring of Gastroesophageal Reflux Disease
The antacids market analysis shows a greater use of digital tools for gastroesophageal reflux disease management. Symptom tracking can help patients identify patterns linked to acid reflux and heartburn. This approach supports more personalized management of indigestion and related stomach acid symptoms.
Alternative Delivery Formats for Antacid Therapies
Antacid products are available in varied formats such as chewable tablets, liquids, and dissolving tablets. These formats provide different options for heartburn treatment and indigestion relief. This product shift is also creating new ways to deliver antacids alongside established proton pump inhibitors and histamine-2 receptor antagonists.
Supply chain disruptions are expected to have a moderate impact on the antacids market share, given its direct exposure to fluctuations in active pharmaceutical ingredients, excipients, packaging materials, aluminum and magnesium compounds, and transportation costs. The market is expected to have a K-shaped recovery as large pharmaceutical manufacturers with diversified supplier networks and stronger procurement capabilities can stabilize production faster. Smaller manufacturers and regional suppliers with limited procurement flexibility remain more exposed to raw material shortages, production delays, and elevated input costs. The market is expected to grow at a CAGR of 4.37%, but supply chain constraints could approximately lower this by 1.5 percentage points, resulting in short-term growth of around 2.87%. As supply conditions normalize through improved raw material availability, more stable logistics costs, and replenished inventories, market growth is expected to gradually return to 4.37%.
The antacids market forecasts strategic investment activity driven by the expansion of gastrointestinal healthcare portfolios, product development, manufacturing capacity, consumer health brands, and commercial distribution networks.
Key Investment and Funding Activities in Antacids Market, 2026
N Zyme Biomedical
USD 4.6 Million
In July 2026, N Zyme Biomedical received USD 4.6 million in Series A financing from investors to advance Phase II clinical programs for laryngopharyngeal reflux and PPI refractory GERD through its pepsin inhibitor platform.
Cinclus Pharma
USD 32 Million
In March 2026, Cinclus Pharma received up to USD 32 million in growth funding from Claret Capital Partners to accelerate Phase III development and prelaunch activities for linaprazan glurate, a treatment for gastric acid-related diseases and GERD.
Dyspepsia Treatment Needs and Easy Access to Over-the-Counter Medications Drive Antacids Market
Stomach discomfort and dyspepsia create a need for quick symptom relief through gastrointestinal drugs. Antacids neutralize stomach acid and can provide relief from symptoms such as heartburn and acid indigestion. The continued need for simple acid neutralizers supports antacid use across digestive health care.
Easy access to OTC medicines allows consumers to obtain antacids without a prescription for mild and occasional symptoms. This availability supports self-care for heartburn, acid indigestion, and related stomach discomfort. As a result, over-the-counter access strengthens the use of antacids for short-term gastrointestinal symptom management.
Side Effects and Product Interaction Risks Restrain Long-Term Usage of Antacids
Side effects linked to some antacid products can limit their frequent or long-term use. Concerns such as constipation, diarrhea, and electrolyte disturbances can affect consumer acceptance and treatment adherence. Consequently, these concerns can slow repeat use and market expansion.
Potential interactions with other medicines can complicate antacid use among patients taking multiple treatments. Certain antacids can affect the absorption or effectiveness of co-administered medicines. These concerns can reduce adoption among patients who require multiple medications.
Expansion of Gastrointestinal Therapeutics and New Format Digestive Health Products Strengthens Opportunities for Antacids Market Players
The broad use of gastrointestinal drugs and over-the-counter (OTC) medicines creates scope for manufacturers to expand antacid product portfolios. Acid neutralizers are widely used for short-term relief from stomach discomfort and dyspepsia. Pharmaceutical companies can develop differentiated OTC formulations for consumers seeking convenient digestive health solutions.
New product formats can support wider applications in gastrointestinal therapeutics and digestive health. Manufacturers can develop chewable tablets, liquid formulations, and combination products for targeted relief of acid-related symptoms. These options can help companies serve different consumer preferences while expanding their presence in the antacids market.
Limited Consumer Awareness about Different Formulations and Product Differentiation Issues Affect Antacids Market Growth
Limited consumer awareness of the differences between antacid products can make product selection difficult, particularly when multiple formulations target similar symptoms. Companies may need to communicate product benefits clearly to maintain visibility and compete effectively across crowded retail and pharmacy channels.
Strong competition among antacid brands can make it difficult for companies to differentiate their products in mature markets. Similar formulations and established brand preferences can limit opportunities for new products to gain recognition and build a strong market position.
The tablet segment accounted for a share of 35.4% in 2025, owing to its convenient dosage and wide availability across pharmacies and retail stores. Its established use for heartburn and acid indigestion supports its leading position.
The effervescent granules segment is expected to grow at a CAGR of 5.47% during the forecast period, driven by fast dissolution and convenient preparation. The preference for easy-to-use antacid formulations also supports segment growth.
Request Customizationto receive a tailored report.
The calcium carbonate segment accounted for a share of 29.8% in 2025 due to its widespread use in antacid formulations and broad product availability. Calcium carbonate is used for rapid relief from heartburn.
The alginate-based segment is expected to grow at a CAGR of 5.39% during the forecast period, fueled by wider use in acid reflux treatment and the ability to form a protective barrier.
The drug stores and retail pharmacies segment accounted for a share of 58.6% in 2025, supported by its wide product availability and easy consumer access. Strong use of OTC antacids supports recurring revenue in drug stores and retail pharmacies.
The e-commerce segment is expected to grow at a CAGR of 6.18% during the forecast period, propelled by convenient product access and home delivery.
Speak to an Analystto discuss market opportunities.
North America: Market Dominance Led by Established Over-the-Counter Availability and Non-prescription Medicines
The North America antacids market accounted for the largest regional share of 34.8%. The region has an established OTC healthcare market and an established non-prescription medicines sector.
The U.S. antacids market benefits from continuous activity across established OTC product lines. Gaviscon received an updated product label, while TUMS Ultra also received an updated label with calcium carbonate as the active antacid ingredient. These product updates reflect continued activity across the U.S. antacids market.
The Canada antacids market benefits from an established non-prescription medicines sector and broad access to digestive health products. Antacids are available in several dosage forms, including chewable tablets, liquids, and combination products for heartburn and acid indigestion. Well-established retail pharmacies and other healthcare channels provide consumers with convenient access to these products.
Unlock Regional Insightsto access country-level data, & regional trends.
Asia Pacific: Fastest Growth Driven by Preference for Self-Care Access and Comprehensive Lifecycle Health Services
The Asia Pacific antacids market is expected to grow at a CAGR of 5.86% during the forecast period, making it the fastest-growing regional market.
The Japan antacids market is expected to benefit from policy changes that could expand self-care access to medicines for gastrointestinal symptoms. Japan’s Ministry of Health, Labour and Welfare is preparing an OTC-like drug insurance reform for implementation in March 2027, with technical discussions covering how medicines with similar OTC indications should be handled, potentially reshaping access and purchasing patterns for non-prescription gastrointestinal treatments.
The China antacids market is expected to benefit from the country’s shift toward health maintenance, disease prevention, and proactive management across the population, which encourages earlier attention to gastrointestinal health and symptom management. China’s 2026–2030 National Health Plan emphasizes comprehensive lifecycle health services, preventive care, health education, and improved access to primary healthcare, supporting broader use of OTC medicines that help manage common gastrointestinal conditions.
The India antacids market is expected to benefit from expanding access to affordable gastrointestinal medicines through the public pharmaceutical distribution network. The Government of India targets 25,000 Jan Aushadhi Kendras by March 2027, with the scheme’s product basket covering gastrointestinal medicines, including antacids and other antiulcer therapies, supporting wider availability of these treatments across the country.
Europe: Market Expansion Led by Established Pharmaceutical Distribution and Community-based Services
The Europe antacids market accounted for a regional share of 27.2%. The region has a well-established medicines sector with multiple antacid formulations available.
The NHS 10-Year Health Plan is shifting care from sickness to prevention and strengthening community-based services, including greater use of community pharmacies for managing long-term conditions. This supports broader access to self-care and gastrointestinal symptom-management options.
The Germany antacids market benefits from established pharmaceutical distribution and access to medicines for digestive disorders. The market includes products formulated with active ingredients such as alginates, calcium carbonate, and magnesium-based compounds for symptom relief.
Latin America: Market Progress Shaped by Robust Regulatory Oversight
The Latin America antacids market is expected to grow at a CAGR of 4.63% during the forecast period. Brazil has an established antacid product base, including aluminum and magnesium hydroxide formulations listed by ANVISA. Mexico is also strengthening medicine access and oversight through COFEPRIS, which launched a real-time database of registered medicines
Middle East & Africa: Market Development Led by Focus on Universal Healthcare Coverage
The Middle East & Africa antacids market is expected to grow at a CAGR of 4.92% during the forecast period. The UAE antacids market is expected to benefit from the country’s emphasis on preventive healthcare, healthy lifestyles, and accessible healthcare under the We the UAE 2031 Vision. The National Strategy for Wellbeing 2031 promotes population-wide health and well-being, supporting broader attention to everyday gastrointestinal health and symptom management.
The African Union’s health agenda prioritizes resilient health systems and equitable access to quality healthcare, supporting wider availability of medicines used to manage common gastrointestinal conditions. For instance, in South Africa, the National Department of Health’s Primary Healthcare Essential Medicines List provides standardized treatment and medicine access through primary healthcare facilities, supporting the availability of medicines for gastrointestinal conditions under the universal health coverage framework.
The antacids market competitive landscape is moderately fragmented, with established peptide manufacturers, biotechnology companies, research peptide suppliers, and specialized antimicrobial peptide developers. Key players such as Haleon, Bayer, Reckitt Benckiser, Opella, and Sun Pharmaceuticals are estimated to account for approximately 42–46% of global antacids market share.
Established players compete through broad product portfolios, regulatory capabilities, manufacturing scale, and pricing. Emerging players in the antacids market ecosystem compete through targeted formulations, product innovation, and digital-first distribution.
June 2026: Bayer's Consumer Health business launched Alka-Seltzer in India, marking the brand's entry into India's OTC digestive-health category.
May 2026: Quest Products officially launched OraHealth Antacid Melts, a stick-on, slow-release antacid designed for nighttime heartburn.
March 2026: Quest Products introduced Antacid Melts, a 250-mg calcium carbonate OTC antacid.
January 2026: P&G added Wonderbelly, an OTC digestive-health brand with a portfolio that includes antacids, to its Personal Health Care portfolio.
Customize This Report to Match Your Strategic Objectives
Author's Details
Senior Research Associate
Dhanshee Bhapkar is a healthcare research professional with 4+ years of experience in market intelligence, specializing in market analysis, secondary research, market estimation, and forecasting across the pharmaceutical, biopharmaceutical, and medical device sectors. She provides actionable insights into market dynamics, competitive intelligence, industry trends, and growth opportunities to support strategic business decision-making.
Her expertise includes assessing market size, growth potential, and revenue opportunities through structured market estimation and forecasting methodologies, including top-down, bottom-up, and epidemiology (EPI)-based approaches. She has hands-on experience analyzing disease epidemiology, treatment landscapes, market trends, competitive scenarios, and industry developments to develop robust market forecasts.
Europe Aesthetic Medicine Market Size, Top Share, Forecast ,2034
Chemical Peel Market Size, Share, Growth, Analysis, Report, 2034
Atopic Dermatitis Treatment Market Size, Share, Growth, 2034
Pigment Dispersion Market Size, Share, Growth, Analysis, 2034
Analgesics Market Size, Share, Growth, Analysis, Report, 2034
Medication Adherence Market Size, Share, Growth, 2034
We are featured on:
sales@straitsresearch.com